KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Bristol Myers Squibb (BMY) Equity Average (2016 - 2025)

Historic Equity Average for Bristol Myers Squibb (BMY) over the last 16 years, with Q3 2025 value amounting to $18.0 billion.

  • Bristol Myers Squibb's Equity Average rose 531.09% to $18.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $18.0 billion, marking a year-over-year increase of 531.09%. This contributed to the annual value of $22.9 billion for FY2024, which is 3854.92% down from last year.
  • Per Bristol Myers Squibb's latest filing, its Equity Average stood at $18.0 billion for Q3 2025, which was up 531.09% from $17.5 billion recorded in Q2 2025.
  • Over the past 5 years, Bristol Myers Squibb's Equity Average peaked at $41.0 billion during Q1 2021, and registered a low of $16.8 billion during Q4 2024.
  • For the 5-year period, Bristol Myers Squibb's Equity Average averaged around $29.2 billion, with its median value being $32.0 billion (2023).
  • Per our database at Business Quant, Bristol Myers Squibb's Equity Average crashed by 4740.44% in 2024 and then skyrocketed by 531.09% in 2025.
  • Quarter analysis of 5 years shows Bristol Myers Squibb's Equity Average stood at $40.8 billion in 2021, then fell by 4.59% to $38.9 billion in 2022, then decreased by 24.84% to $29.3 billion in 2023, then tumbled by 42.63% to $16.8 billion in 2024, then grew by 7.45% to $18.0 billion in 2025.
  • Its last three reported values are $18.0 billion in Q3 2025, $17.5 billion for Q2 2025, and $16.9 billion during Q1 2025.